Charsire New Drug ACA for
CANCER RADIOTHERAPY SKIN REACTIONS
Charsire new drug ACA for cancer radiotherapy skin reactions has completed phase I clinical study. The study results suggested that ACA can effectively reduce side effects caused by radiotherapy, such as pain or skin reactions, and improve the quality and effectiveness of treatment for patients with radiotherapy.
Statistical data indicates that about 50% of cancer patients are required to receive radiotherapy to control tumor. The side effects casued during radiotherapy treatment often results in treatment interruption, which may reduce the effect on tumor inhibition. ACA was proven to effectively improve the local tumor control and survival rate of cancer patients by reducing the side effects caused by radiotherapy treatment.
Pre-clinical pharmacological studies
Toxicology tests for phase II and phase III, completed
Phase I clinical study approved by TW FDA, completed
Overview & Medication Predicament:：
Long Healing Period &
High Risk of Infection
A radiotherapy treatment course usually takes five to eight weeks, and patients’ condition determines both the dose and range of radiation. An effective radiotherapy treatment requires a series of fractional therapies which often cause different side effects during radiotherapy treatment, resulting in pain and discomfort, leading to interruption of treatment and reducing the effect of tumor treatment.
The pain medications currently used to control the side effects of the radiotherapy mostly reduce pain by directly inhibiting the central nervous system or inhibiting inflammation, but both leads to various side effects. For dermatitis and fibrosis caused by radiotherapy, existing products such as aloe vera, moisturizer, evidently reduce patient discomfort without effective treatment.
Core Technology of ACA
Cancer Radiotherapy Pain & Skin Reactions New Drug (ACA) Reduces Radiotherapy Skin Damage by Reducing IL-1β, TNF-α and Oxidative Stress for Radiation Inflammation.
Improve the side effects of radiotherapy
Worldwide cancer population is about 18 million, and 50% of cancer patients will receive radiation therapy, while 80-100% of them will develop skin reactions. Each year, about 7.5 million cancer radiotherapy patients develop skin dermatitis and pain due to radiation.
ACA can reduce skin inflammation and pain caused by radiation, and can be further applied to skin damage that may occur after aesthetic laser treatment, such as redness, scorching heat, swelling, and pigmentations. ACA can effectively repair skin wounds after laser treatment, improve wounds recovery and enhance the effect of the treatment.